Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.81 USD
−14.63 M USD
2.46 M USD
3.34 M
About Neuraxis, Inc.
Sector
Industry
CEO
Brian Carrico
Website
Headquarters
Carmel
Founded
2011
FIGI
BBG01C9N12C3
NeurAxis, Inc. develops neuromodulation therapies to address chronic and debilitating conditions in children. Its product IB-Stim is a non-surgical device that works by sending gentle electrical impulses into cranial nerve bundles located in the ear. The company was founded by Gary Peterson and Christopher Robin Brown in 2011 and is headquartered in Carmel, IN.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of NRXS is 2.58 USD — it has decreased by −7.48% in the past 24 hours. Watch Neuraxis, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on AMEX exchange Neuraxis, Inc. stocks are traded under the ticker NRXS.
NRXS stock has fallen by −13.65% compared to the previous week, the month change is a 4.62% rise, over the last year Neuraxis, Inc. has showed a −5.49% decrease.
NRXS reached its all-time high on Aug 9, 2023 with the price of 6.93 USD, and its all-time low was 1.80 USD and was reached on Oct 26, 2023. View more price dynamics on NRXS chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
NRXS stock is 6.59% volatile and has beta coefficient of −1.27. Track Neuraxis, Inc. stock price on the chart and check out the list of the most volatile stocks — is Neuraxis, Inc. there?
Yes, you can track Neuraxis, Inc. financials in yearly and quarterly reports right on TradingView.
Neuraxis, Inc. is going to release the next earnings report on Apr 15, 2025. Keep track of upcoming events with our Earnings Calendar.
Neuraxis, Inc. revenue for the last quarter amounts to 666.63 K USD, despite the estimated figure of 3.14 M USD. In the next quarter, revenue is expected to reach 3.62 M USD.
NRXS net income for the last quarter is −1.76 M USD, while the quarter before that showed −2.92 M USD of net income which accounts for 39.84% change. Track more Neuraxis, Inc. financial stats to get the full picture.
No, NRXS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 12, 2024, the company has 19.00 employees. See our rating of the largest employees — is Neuraxis, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Neuraxis, Inc. EBITDA is −7.27 M USD, and current EBITDA margin is −269.25%. See more stats in Neuraxis, Inc. financial statements.
Like other stocks, NRXS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Neuraxis, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Neuraxis, Inc. technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Neuraxis, Inc. stock shows the strong sell signal. See more of Neuraxis, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.